Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Review Article

How can we Preserve Sexual Function after Ablative Surgery for Benign Prostatic Hyperplasia?

Author(s): Ioannis Mykoniatis*, Koenraad Van Renterghem and Ioannis Sokolakis

Volume 22 , Issue 1 , 2021

Published on: 25 September, 2020

Page: [4 - 13] Pages: 10

DOI: 10.2174/1389450121666200925143916

Price: $65

Abstract

Our aim was to provide a narrative review regarding the prevalence, the associated pathophysiologic pathways and the potential management methods of sexual dysfunction related to ablative surgical techniques for Benign Prostatic Enlargement (BPE). Men suffering from BPE are at high risk of sexual dysfunction due to the disease itself, comorbidities, and pharmacological/surgical treatments. Transurethral resection of the prostate, as the gold standard treatment option for BPE, has historically been associated with relatively high rates of postoperative sexual dysfunction problems, mainly retrograde ejaculation but also erectile dysfunction. Ablative surgical techniques, including photoselective vaporization of the prostate (PVP), transurethral needle ablation (TUNA), Transurethral Microwave Therapy (TUMT), Convective Water Vapor Energy Ablation (Rezum®) and Aquablation®, have been proposed as treatment methods able to reduce treatment-related complications for BPE patients, including adverse effects on erectile and ejaculatory function, without compromising the efficacy rates for BPE. The neurovascular bundles can be damaged during TURP due to posterolateral capsular perforation. Ablative techniques and especially PVP theoretically seem to skip this hazard, as the distance created from the necrotic area to the capsule is generally larger compared to the distance induced after TURP. However, indirect thermal injury of erectile nerves, which could also be induced by the majority of available ablative techniques, could potentially lead to ED. Two special technical characteristics (physiological saline use for tissue ablation and real time penetration depth control) of Aquablation® could be proved beneficial with regard to the effect of the method on erectile function. In general, ablative techniques seem to have a minor impact on sexual function. However, low methodological quality characterizes most of the studies included in this review mainly due to the impossibility, in many cases, to perform blind randomization. Also, many studies did not have an erectile and ejaculatory function as primary outcomes limiting that way their statistical power to identify significant variations. Management of sexual dysfunction problems arising from ablative surgeries for BPE treatment could be divided into two levels. Firstly, intraoperatively the avoidance of manipulation of crucial structures regarding ejaculatory (bladder neck or ejaculatory ducts) and erectile function (neurovascular bundles) could possibly decrease the negative effect of these procedures on sexual function. Thus, in this direction, modifications of classic ablative techniques have been proposed resulting in encouraging outcomes regarding postoperative sexual function. Secondly, if EjD and/or ED are established, the already known treatment choices should be chosen in order for sexual function rehabilitation to be achieved. Thus, regarding ED: PDE5i daily or on-demand remains the gold standard first-line treatment choice followed by intracavernosal alprostadil injections in cases of failure, while penile prosthesis implantation must be kept as the final definitive solution when all the other methods have failed. Regarding ejaculation disorders (retrograde ejaculation or anejaculation): medical therapy with a-agonists (pseudoephedrine), sperm retrieval from the urine, bladder neck reconstruction, prostatic massage, electroejaculation, penile vibratory stimulation and surgical sperm retrieval are the available treatment options. Furthermore, high-quality studies are required to investigate the potential side effects of BPE surgery on sexual function and efficient treatment methods to manage them.

Keywords: Benign Prostatic Enlargement (BPE), prostate (PVP), transurethral needle ablation (TUNA), Transurethral Microwave Therapy (TUMT), Aquablation, alprostadil injections.

Graphical Abstract
[1]
De Nunzio, C.; Roehrborn, C.G.; Andersson, K-E.; McVary, K.T. Erectile dysfunction and lower urinary tract symptoms. Eur. Urol. Focus, 2017, 3(4-5), 352-363.
[http://dx.doi.org/10.1016/j.euf.2017.11.004] [PMID: 29191671]
[2]
Liao, L.; Chuang, Y-C.; Liu, S-P. Effect of lower urinary tract symptoms on the quality of life and sexual function of males in China, Taiwan, and South Korea: Subgroup analysis of a cross-sectional, population-based study. Low. Urin. Tract Symptoms, 2019, 11(2), O78-O84.
[http://dx.doi.org/10.1111/luts.12220] [PMID: 29527813]
[3]
Zhao, H.; Kim, H.H. The complex relationship between lower urinary tract symptoms and sexual health. Curr. Urol. Rep., 2019, 20(10), 58.
[http://dx.doi.org/10.1007/s11934-019-0930-4] [PMID: 31468204]
[4]
Gomes, C.M.; Averbeck, M.A.; Koyama, M.; Soler, R. Association among lower urinary tract symptoms, erectile function, and sexual satisfaction: Results from the Brazil LUTS study. Sex. Med., 2020, 8(1), 45-56.
[http://dx.doi.org/10.1016/j.esxm.2019.09.003] [PMID: 31810862]
[5]
Braun, M.; Wassmer, G.; Klotz, T.; Reifenrath, B.; Mathers, M.; Engelmann, U. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int. J. Impot. Res., 2000, 12(6), 305-311.
[http://dx.doi.org/10.1038/sj.ijir.3900622] [PMID: 11416833]
[6]
Borchert, A.; Leavitt, D.A. A review of male sexual health and dysfunction following surgical treatment for benign prostatic hyperplasia and lower urinary tract symptoms. Curr. Urol. Rep., 2018, 19(8), 66.
[http://dx.doi.org/10.1007/s11934-018-0813-0] [PMID: 29923036]
[7]
Roehrborn, C.G.; Manyak, M.J.; Palacios-Moreno, J.M. A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int., 2018, 121(4), 647-658.
[http://dx.doi.org/10.1111/bju.14057] [PMID: 29044968]
[8]
Chung, A.; Woo, H.H. Preservation of sexual function when relieving benign prostatic obstruction surgically: can a trade-off be considered? Curr. Opin. Urol., 2016, 26(1), 42-48.
[http://dx.doi.org/10.1097/MOU.0000000000000247] [PMID: 26555693]
[9]
Bruyère, F.; Puichaud, A.; Pereira, H. Influence of photoselective vaporization of the prostate on sexual function: results of a prospective analysis of 149 patients with long-term follow-up. Eur. Urol., 2010, 58(2), 207-211.
[http://dx.doi.org/10.1016/j.eururo.2010.04.027] [PMID: 20466480]
[10]
Parnham, A.; Serefoglu, E.C. Retrograde ejaculation, painful ejaculation and hematospermia. Transl. Androl. Urol., 2016, 5(4), 592-601.
[http://dx.doi.org/10.21037/tau.2016.06.05] [PMID: 27652230]
[11]
Bieri, S.; Iselin, C.E.; Rohner, S. Capsular perforation localization and adenoma size as prognostic indicators of erectile dysfunctional after transurethral prostatectomy. Scand. J. Urol. Nephrol., 1997, 31(6), 545-548.
[http://dx.doi.org/10.3109/00365599709030660] [PMID: 9458513]
[12]
Bruyère, F. The relationship between photoselective vaporization of the prostate and sexual function. Curr. Urol. Rep., 2011, 12(4), 261-264.
[http://dx.doi.org/10.1007/s11934-011-0199-8] [PMID: 21656206]
[13]
Pavone, C.; Abbadessa, D.; Scaduto, G. Sexual dysfunctions after transurethral resection of the prostate (TURP): evidence from a retrospective study on 264 patients. Arch. Ital. Urol. Androl., 2015, 87(1), 8-13.
[http://dx.doi.org/10.4081/aiua.2015.1.8] [PMID: 25847889]
[14]
Lefaucheur, J.P.; Yiou, R.; Salomon, L.; Chopin, D.K.; Abbou, C.C. Assessment of penile small nerve fiber damage after transurethral resection of the prostate by measurement of penile thermal sensation. J. Urol., 2000, 164(4), 1416-1419.
[http://dx.doi.org/10.1016/S0022-5347(05)67209-6] [PMID: 10992425]
[15]
Roehrborn, CG; Teplitsky, S; Das, AK Aquablation of the prostate: a review and update. Can J Urol., 2019, 26(AS1), 20-4.
[16]
Soleimani, M.; Hosseini, S.Y.; Aliasgari, M.; Dadkhah, F.; Lashay, A.; Amini, E. Erectile dysfunction after prostatectomy: an evaluation of the risk factors. Scand. J. Urol. Nephrol., 2009, 43(4), 277-281.
[http://dx.doi.org/10.1080/00365590902930824] [PMID: 19404865]
[17]
Thomas, J.A.; Tubaro, A.; Barber, N. A Multicenter randomized noninferiority trial comparing greenLight-XPS laser vaporization of the prostate and transurethral resection of the prostate for the treatment of benign prostatic obstruction: Two-yr outcomes of the GOLIATH study. Eur. Urol., 2016, 69(1), 94-102.
[http://dx.doi.org/10.1016/j.eururo.2015.07.054] [PMID: 26283011]
[18]
Te, A.E.; Malloy, T.R.; Stein, B.S. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. J. Urol., 2004, 172(4 Pt 1), 1404-1408.
[http://dx.doi.org/10.1097/01.ju.0000139541.68542.f6] [PMID: 15371855]
[19]
Bachmann, A.; Schürch, L.; Ruszat, R. Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome. Eur. Urol., 2005, 48(6), 965-971.
[http://dx.doi.org/10.1016/j.eururo.2005.07.001] [PMID: 16126327]
[20]
Malek, R.S.; Kuntzman, R.S.; Barrett, D.M. Photoselective potassium-titanyl-phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J. Urol., 2005, 174(4 Pt 1), 1344-1348.
[http://dx.doi.org/10.1097/01.ju.0000173913.41401.67] [PMID: 16145416]
[21]
Paick, J-S.; Um, J.M.; Kim, S.W.; Ku, J.H. Influence of high-power potassium-titanyl-phosphate photoselective vaporization of the prostate on erectile function: a short-term follow-up study. J. Sex. Med., 2007, 4(6), 1701-1707.
[http://dx.doi.org/10.1111/j.1743-6109.2007.00574.x] [PMID: 17672845]
[22]
Rosen, R.C.; Riley, A.; Wagner, G.; Osterloh, I.H.; Kirkpatrick, J.; Mishra, A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology, 1997, 49(6), 822-830.
[http://dx.doi.org/10.1016/S0090-4295(97)00238-0] [PMID: 9187685]
[23]
Rosen, R.C.; Cappelleri, J.C.; Smith, M.D.; Lipsky, J.; Peña, B.M. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int. J. Impot. Res., 1999, 11(6), 319-326.
[http://dx.doi.org/10.1038/sj.ijir.3900472] [PMID: 10637462]
[24]
Kavoussi, P.K.; Hermans, M.R. Maintenance of erectile function after photoselective vaporization of the prostate for obstructive benign prostatic hyperplasia. J. Sex. Med., 2008, 5(11), 2669-2671.
[http://dx.doi.org/10.1111/j.1743-6109.2008.00978.x] [PMID: 18785895]
[25]
Ouyang, Y.; Liu, C.; Guan, W.; Zhao, Y.; Xu, Y.; Wu, Y. Impact of 160 W Greenlight laser vaporization of the prostate on erectile function: a prospective randomized controlled trial with 1-year follow-up. Photomed. Laser Surg., 2014, 32(8), 463-467.
[http://dx.doi.org/10.1089/pho.2014.3727] [PMID: 25101536]
[26]
Kumar, A.; Vasudeva, P.; Kumar, N.; Nanda, B.; Jha, S.K.; Mohanty, N. A prospective randomized comparative study of monopolar and bipolar transurethral resection of the prostate and photoselective vaporization of the prostate in patients who present with benign prostatic obstruction: a single center experience. J. Endourol., 2013, 27(10), 1245-1253.
[http://dx.doi.org/10.1089/end.2013.0216] [PMID: 23746047]
[27]
Hossack, T.A.; Woo, H.H. Sexual function outcome following photoselective vaporisation of the prostate. Int. Urol. Nephrol., 2012, 44(2), 359-364.
[http://dx.doi.org/10.1007/s11255-011-0029-4] [PMID: 21779921]
[28]
Kumar, A.; Vasudeva, P.; Kumar, N.; Nanda, B.; Mohanty, N.K. Evaluation of the effect of photoselective vaporization of the prostate on sexual function in a prospective study: A single center experience of 150 patients. J. Endourol., 2012.
[http://dx.doi.org/10.1089/end.2012.0376] [PMID: 22849319]
[29]
Kumar, A.; Vasudeva, P.; Kumar, N. A prospective study on the effect of photoselective vaporization of prostate by 120-W high-performance system laser on sexual function. J. Endourol., 2014, 28(9), 1115-1120.
[http://dx.doi.org/10.1089/end.2014.0170] [PMID: 24754237]
[30]
Li, Z.; Chen, P.; Wang, J.; Mao, Q. The impact of surgical treatments for lower urinary tract symptoms/benign prostatic hyperplasia on male erectile function: A systematic review and network meta-analysis. Medicine (Baltimore), 2016, 95(24), e3862.
[http://dx.doi.org/10.1097/MD.0000000000003862] [PMID: 27310968]
[31]
Lai, S; Peng, P; Diao, T; Hou, H; Wang, X; Zhang, W Comparison of photoselective green light laser vaporisation versus traditional transurethral resection for benign prostate hyperplasia: an updated systematic review and meta-analysis of randomised controlled trials and prospective studies. BMJ Open, 2019, 9(8), e02885.
[http://dx.doi.org/10.1136/bmjopen-2018-028855]
[32]
Bruskewitz, R.; Issa, M.M.; Roehrborn, C.G. A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J. Urol., 1998, 159(5), 1588-1593.
[http://dx.doi.org/10.1097/00005392-199805000-00048] [PMID: 9554360]
[33]
Hill, B.; Belville, W.; Bruskewitz, R.; Issa, M.; Perez-Marrero, R.; Roehrborn, C.; Terris, M.; Naslund, M. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J. Urol., 2004, 171(6 Pt 1), 2336-2340.
[http://dx.doi.org/10.1097/01.ju.0000127761.87421.a0] [PMID: 15126816]
[34]
Cimentepe, E.; Unsal, A.; Saglam, R. Randomized clinical trial comparing transurethral needle ablation with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: results at 18 months. J. Endourol., 2003, 17(2), 103-107.
[http://dx.doi.org/10.1089/08927790360587432] [PMID: 12689404]
[35]
Frieben, R.W.; Lin, H-C.; Hinh, P.P.; Berardinelli, F.; Canfield, S.E.; Wang, R. The impact of minimally invasive surgeries for the treatment of symptomatic benign prostatic hyperplasia on male sexual function: a systematic review. Asian J. Androl., 2010, 12(4), 500-508.
[http://dx.doi.org/10.1038/aja.2010.33] [PMID: 20473318]
[36]
Bouza, C.; López, T.; Magro, A.; Navalpotro, L.; Amate, J.M. Systematic review and meta-analysis of Transurethral Needle Ablation in symptomatic Benign Prostatic Hyperplasia. BMC Urol., 2006, 6, 14.
[http://dx.doi.org/10.1186/1471-2490-6-14] [PMID: 16790044]
[37]
Francisca, E.A.; d’Ancona, F.C.; Meuleman, E.J.; Debruyne, F.M.; de la Rosette, J.J. Sexual function following high energy microwave thermotherapy: results of a randomized controlled study comparing transurethral microwave thermotherapy to transurethral prostatic resection. J. Urol., 1999, 161(2), 486-490.
[http://dx.doi.org/10.1016/S0022-5347(01)61930-X] [PMID: 9915432]
[38]
Mynderse, L.A.; Roehrborn, C.G.; Partin, A.W.; Preminger, G.M.; Coté, E.P. Results of a 5-year multicenter trial of a new generation cooled high energy transurethral microwave thermal therapy catheter for benign prostatic hyperplasia. J. Urol., 2011, 185(5), 1804-1810.
[http://dx.doi.org/10.1016/j.juro.2010.12.054] [PMID: 21420115]
[39]
Hoffman, R.M.; Monga, M.; Elliott, S.P. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst. Rev., 2012, (9), CD004135.
[PMID: 22972068]
[40]
Westwood, J.; Geraghty, R.; Jones, P.; Rai, B.P.; Somani, B.K. Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. Ther. Adv. Urol., 2018, 10(11), 327-333.
[http://dx.doi.org/10.1177/1756287218793084] [PMID: 30344644]
[41]
McVary, K.T.; Rogers, T.; Roehrborn, C.G. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology, 2019, 126, 171-179.
[http://dx.doi.org/10.1016/j.urology.2018.12.041] [PMID: 30677455]
[42]
Rosen, R.C.; Catania, J.; Pollack, L.; Althof, S.; O’Leary, M.; Seftel, A.D. Male sexual health questionnaire (MSHQ): scale development and psychometric validation. Urology, 2004, 64(4), 777-782.
[http://dx.doi.org/10.1016/j.urology.2004.04.056] [PMID: 15491719]
[43]
McVary, K.T.; Gange, S.N.; Gittelman, M.C. Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Randomized controlled study. J. Sex. Med., 2016, 13(6), 924-933.
[http://dx.doi.org/10.1016/j.jsxm.2016.03.372] [PMID: 27129767]
[44]
McVary, K.T.; Rogers, T.; Mahon, J.; Gupta, N.K. Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia? J. Sex. Med., 2018, 15(12), 1728-1738.
[http://dx.doi.org/10.1016/j.jsxm.2018.10.006] [PMID: 30446471]
[45]
Darson, M.F.; Alexander, E.E.; Schiffman, Z.J. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezūm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Res. Rep. Urol., 2017, 9, 159-168.
[http://dx.doi.org/10.2147/RRU.S143679] [PMID: 28861405]
[46]
Dixon, C.M.; Cedano, E.R.; Pacik, D. Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Res. Rep. Urol., 2016, 8, 207-216.
[http://dx.doi.org/10.2147/RRU.S119596] [PMID: 27921028]
[47]
Mollengarden, D.; Goldberg, K.; Wong, D.; Roehrborn, C. Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience. Prostate Cancer Prostatic Dis., 2018, 21(3), 379-385.
[http://dx.doi.org/10.1038/s41391-017-0022-9] [PMID: 29282358]
[48]
Roehrborn, C.G.; Gange, S.N.; Gittelman, M.C. Convective thermal therapy: Durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J. Urol., 2017, 197(6), 1507-1516.
[http://dx.doi.org/10.1016/j.juro.2016.12.045] [PMID: 27993667]
[49]
MacRae, C.; Gilling, P. How I do it: Aquablation of the prostate using the AQUABEAM system. Can. J. Urol., 2016, 23(6), 8590-8593.
[PMID: 27995858]
[50]
Gilling, P.; Reuther, R.; Kahokehr, A.; Fraundorfer, M. Aquablation - image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int., 2016, 117(6), 923-929.
[http://dx.doi.org/10.1111/bju.13358] [PMID: 26477826]
[51]
Gilling, P.; Barber, N.; Bidair, M. WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. J. Urol., 2018, 199(5), 1252-1261.
[http://dx.doi.org/10.1016/j.juro.2017.12.065] [PMID: 29360529]
[52]
Gilling, P.J.; Barber, N.; Bidair, M. Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-year Outcomes. Urology, 2019, 125, 169-173.
[http://dx.doi.org/10.1016/j.urology.2018.12.002] [PMID: 30552937]
[53]
Xu, Z.; Liu, J.; Zheng, X.; Pu, X. Protective effect of preserving bladder neck integrity on erectile function in patients undergoing plasmakinetic vaporization for benign prostatic hyperplasia. Nan Fang Yi Ke Da Xue Xue Bao, 2014, 34(11), 1702-1704.
[PMID: 25413079]
[54]
V403: The impact of Ejaculation-Preserving Photo-selective Vaporization of the Prostate (EP-PVP) on lower | AUA University, https://auau.auanet.org/content/v403-impact-ejaculation-preserving-photo-selective-vaporization-prostate-ep-pvp-lower
[55]
Mehta, A.; Sigman, M. Management of the dry ejaculate: a systematic review of aspermia and retrograde ejaculation. Fertil. Steril., 2015, 104(5), 1074-1081.
[http://dx.doi.org/10.1016/j.fertnstert.2015.09.024] [PMID: 26432530]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy